Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders

Launched by HEALEON MEDICAL INC · Oct 25, 2016

Keywords

ClinConnect Summary

COPD is often treated by limiting exposure to poor air quality, but there is no cure at this time. Attempted therapy include smoking cessation, vaccinations, respiratory rehabilitation, and attempts of use of bronchodilators and steroids. Many resort to supplemental oxygen therapy, lung transplantation, and antibiotic supportive therapy during exacerbations.

As of 2013, COPD involve approximately 5% pf the global populations (approximately 330 million). Most commonly it occurs approximately equally between men/women and result in about 3 million deaths per year. Estimates of economic costs...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Prior Diagnosis of moderate to severe COPD
• • GOLD II a, III, IV
• Exclusion Criteria:
• • Pregnant or Lactating Females
• • Life expectancy of \< 3 months due to concomitant illnesses
• • Exposure to any investigational drug or procedure with 1 month prior to study entry or enrollment in concurrent study which may interfere with interpretation of study results
• • Illness which, in investigators judgement, may interfere with the patient' ability to comply with protocol, compromise patient safety, ability to provide informed consent to study, or interfere with interpretation of study outcomes
• • Subjects on chronic immunosuppressive or chemotherapeutic medications
• • Known drug or alcohol dependence or other factors which may interfere with study conduct or interpretation of result or in the opinion of investigator are not suitable to participate.
• • Subjects with documented Alpha-1 Antitrypsin Deficiency (Inherited lung and liver disorder)
• • Unwilling or not competent to understand and execute an informed consent agreement
• • Patients positive for Hepatitis (Hepatitis A history excepted)